Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell vaccine
- Development stage
- Unknown
- Lead developer
- Case Comprehensive Cancer Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, Peptides
- Administration
- Intradermal
01
Overview
The tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell vaccine (DC-TBVA) is an experimental autologous, personalized cancer immunotherapy. It is manufactured by isolating a patient's own peripheral blood mononuclear cells, generating alpha-type-1 polarized dendritic cells (alphaDC1s) ex vivo, and pulsing them with six HLA-A2-restricted tumor blood vessel antigen (TBVA)-derived peptides: DLK1, EphA2, HBB, NRP1, RGS5, and TEM1. Unlike traditional cancer vaccines that target tumor cells directly, this vaccine targets the tumor stroma, specifically HLA-A2+ pericytes and vascular endothelial cells, with the goal of inducing CD8+ T cell-mediated immunity to disrupt the tumor microenvironment and blood supply. It has been investigated in Phase 1 clinical trials for metastatic breast cancer, often in combination with gemcitabine to suppress myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs).
- Other names
- autologous alpha-DC1/TBVA vaccine
02
Targets
HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)Tumor vasculature and stroma-associated HLA-A*02:01-restricted peptides
Beyond the preview
Go deeper on tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell vaccine.